Search Results - "Kaisermann, M. C."

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    IgA antibody responses to Mycobacterium tuberculosis recombinant MPT-64 and MT-10.3 (Rv3019c) antigens in pleural fluid of patients with tuberculous pleurisy

    IgA antibody responses to Mycobacterium tuberculosis recombinant MPT-64 and MT-10.3 (Rv3019c) antigens in pleural fluid of patients with tuberculous pleurisy by KAISERMANN, M. C, SARDELLA, I. G, TRAJMAN, A, COELHO, L. V, KÄMPFER, S, JONAS, F, SINGH, M, SAAD, M. H. F

    “…SETTING: Microbiological tests lack sensitivity for pleural tuberculosis (TB) and histopathology is expensive, time consuming and needs specialised personnel…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

    P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA by Usmani, S. Z., Mielnik, M., Koh, Y., Alonso Alonso, A., Leleu, X., Quach, H., Min, C.-K., Janowski, W., Abdallah, A.-O., Garg, M., Sandhu, I., Ocio San Miguel, E. M., Oriol, A., Rodriquez-Otero, P., Ramasamy, K., Weisel, K., Besemer, B., Cavo, M., Zhou, X. L., Kaisermann, M. C., Bego Marques, C. M., Williams, D., Carreno, F., Kremer, B. E., Gupta, I. V., Hus, M.

    Published in HemaSphere (23-06-2022)
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    Evolving features of lung adenocarcinoma in Rio de Janeiro, Brazil

    Evolving features of lung adenocarcinoma in Rio de Janeiro, Brazil by Kaisermann, M C, Trajman, A, Madi, K

    Published in Oncology reports (01-01-2001)
    “…Formerly considered rare, adenocarcinoma has become the commonest form of primary lung cancer in developed countries. Its clinical presentation has changed,…”
    Get more information
    Journal Article
    Save to List
    Saved in:
  4. 4
    P942: DREAMM‐9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

    P942: DREAMM‐9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA by Usmani, S. Z., Mielnik, M., Koh, Y., Alonso Alonso, A., Leleu, X., Quach, H., Min, C.‐K., Janowski, W., Abdallah, A.‐O., Garg, M., Sandhu, I., Ocio San Miguel, E. M., Oriol, A., Rodriquez‐Otero, P., Ramasamy, K., Weisel, K., Besemer, B., Cavo, M., Zhou, X. L., Kaisermann, M. C., Bego Marques, C. M., Williams, D., Carreno, F., Kremer, B. E., Gupta, I. V., Hus, M.

    Published in HemaSphere (01-06-2022)
    Get full text
    Journal Article
    Save to List
    Saved in:
  5. 5
    Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD

    Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD by Bansal, Sandeep, Anderson, Martin, Anzueto, Antonio, Brown, Nicola, Compton, Chris, Corbridge, Thomas C., Erb, David, Harvey, Catherine, Kaisermann, Morrys C., Kaye, Mitchell, Lipson, David A., Martin, Neil, Zhu, Chang-Qing, Papi, Alberto

    Published in NPJ primary care respiratory medicine (25-05-2021)
    “…Chronic obstructive pulmonary disease (COPD) treatment guidelines do not currently include recommendations for escalation directly from monotherapy to triple…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: